Literature DB >> 19415182

Possible contribution of beta-glycosidases and caspases in the cytotoxicity of novel glycoconjugates in colon cancer cells.

Hossam M M Arafa1.   

Abstract

Glycoconjugates represent a recent trend in cancer chemotherapy that adopts the concept of selective prodrug/drug targeting of tumor cells by selectively binding to specific transmembrane glucose transporters. Following preferential uptake of sugar conjugates into cancer cells, they are presumably subject to enzymatic cleavage by specific beta-glycosidases to liberate the free active cytotoxic aglycones that act selectively on cancer cells and spare other noncancerous ones. In this sense, the cytotoxicity of an array of newly synthesized glycoconjugates, including curcumin beta-glucoside, perillyl alcohol beta-glucoside, perillyl alcohol beta-galactoside, diethylstilbesterol beta-glucoside and diethylstilbesterol beta-galactoside have been investigated over 24-96 h in a panel of human colon cancer cells namely, Caco-2, HT29 and T84 cells. The role of beta-glycosidases and caspases in the bioactivation and cytotoxicity of these compounds has been addressed in the current study. All the glycoconjugates have proven cytotoxic efficacy in a time-dependent manner. Curcumin beta-glucoside was the most potent amongst all glycoconjugates tested. The sensitivity rank order of tumor cells towards all beta-glucosides was Caco-2 > HT29 > T84. This sensitivity ranking was well correlated with beta-glucosidase activity assessed in these cell lines. Unlike perillyl alcohol galactoside, the cytotoxicity rank order for diethylstilbesterol beta-galactoside was not coping with the beta-galactosidase activity detected. Apoptosis was assessed by fluorometric assay of caspase-3 and caspase-9 activities. Initiation and activation of apoptosis were increased in all colon cancer cells following exposure to most of the glycoconjugates, and this was well correlated with the cytotoxicity rank order of these prodrugs. Enzymatic cleavage of glycoconjugates was accomplished using a host of hydrolytic enzymes and cleavage kinetics was determined using HPLC. The glycoconjugates were only cleaved by beta-glucosidases and beta-galactosidases, but not by pancreatic lipase or hepatic esterase. Taken together, one could conclude that beta-glucosidases and beta-galactosidases are crucial for the bioactivation and cytotoxicity of these glycoconjugates. Also, initiation and activation of apoptosis in tumor cells may contribute, at least partly, for the cytotoxicity of these sugar conjugates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415182     DOI: 10.1007/s10637-009-9248-2

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  39 in total

1.  Possible errors in assay for beta-glycosidase activity.

Authors:  R W Chadwick; J C Allison; D L Talley; S E George
Journal:  Appl Environ Microbiol       Date:  1995-02       Impact factor: 4.792

2.  Evaluation of beta-galactosidase activity in tissue in the presence of blood.

Authors:  J Pelisek; S Armeanu; S Nikol
Journal:  J Vasc Res       Date:  2000 Nov-Dec       Impact factor: 1.934

3.  Effect of steroid hormones on human colorectal adenocarcinoma xenografts, of known steroid-receptor status, in nude mice.

Authors:  W S Stebbings; G P Vinson; M J Farthing; F Balkwill; R F Wood
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

4.  Antiapoptotic effects of estrogen in normal and cancer human cervical epithelial cells.

Authors:  Qifang Wang; Xin Li; Liqin Wang; Ying-Hong Feng; Robin Zeng; George Gorodeski
Journal:  Endocrinology       Date:  2004-08-19       Impact factor: 4.736

5.  Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.

Authors:  Jun Wu; Yanhui Lu; Alice Lee; Xiaogang Pan; Xiaojuan Yang; Xiaobin Zhao; Robert J Lee
Journal:  J Pharm Pharm Sci       Date:  2007       Impact factor: 2.327

6.  Intestinal absorption of acyclovir beta-glucoside: comparative study with acyclovir, guanosine, and kinetin beta-glucoside.

Authors:  T Mizuma; S Masubuchi; S Awazu
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

7.  Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy.

Authors:  Harikrishna Devalapally; Kombu Subramanian Rajan; Raghuram Rao Akkinepally; Rama Krishna Devarakonda
Journal:  Drug Dev Ind Pharm       Date:  2008-08       Impact factor: 3.225

8.  Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma.

Authors:  Wen-Lung Ma; Cheng-Lung Ma; Cheng-Lung Hsu; Ming-Heng Wu; Chun-Te Wu; Cheng-Chia Wu; Jiann-Jyh Lai; Yuh-Shan Jou; Chun-Wei Chen; Shuyuan Yeh; Chawnshang Chang
Journal:  Gastroenterology       Date:  2008-05-22       Impact factor: 22.682

Review 9.  Paul Ehrlich's magic bullet concept: 100 years of progress.

Authors:  Klaus Strebhardt; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2008-05-12       Impact factor: 60.716

Review 10.  Sugar and fat - that's where it's at: metabolic changes in tumors.

Authors:  Christian D Young; Steven M Anderson
Journal:  Breast Cancer Res       Date:  2008-02-20       Impact factor: 6.466

View more
  5 in total

Review 1.  Curcumin and Derivatives in Nanoformulations with Therapeutic Potential on Colorectal Cancer.

Authors:  Sourour Idoudi; Takwa Bedhiafi; Yousef Mohammad Hijji; Nashiru Billa
Journal:  AAPS PharmSciTech       Date:  2022-04-19       Impact factor: 3.246

Review 2.  Perspectives on new synthetic curcumin analogs and their potential anticancer properties.

Authors:  Alok Vyas; Prasad Dandawate; Subhash Padhye; Aamir Ahmad; Fazlul Sarkar
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 3.  8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications.

Authors:  Veda Prachayasittikul; Supaluk Prachayasittikul; Somsak Ruchirawat; Virapong Prachayasittikul
Journal:  Drug Des Devel Ther       Date:  2013-10-04       Impact factor: 4.162

4.  The identification of perillyl alcohol glycosides with improved antiproliferative activity.

Authors:  Nitin S Nandurkar; Jianjun Zhang; Qing Ye; Larissa V Ponomareva; Qing-Bai She; Jon S Thorson
Journal:  J Med Chem       Date:  2014-08-25       Impact factor: 7.446

Review 5.  The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers.

Authors:  Thomas C Chen; Clovis O da Fonseca; Daniel Levin; Axel H Schönthal
Journal:  Pharmaceutics       Date:  2021-12-16       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.